Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Traws Pharma (TRAW) Income towards Parent Company (2016 - 2025)

Historic Income towards Parent Company for Traws Pharma (TRAW) over the last 14 years, with Q3 2025 value amounting to -$4.1 million.

  • Traws Pharma's Income towards Parent Company rose 5249.53% to -$4.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$15.8 million, marking a year-over-year increase of 8884.91%. This contributed to the annual value of -$142.4 million for FY2024, which is 60141.89% down from last year.
  • Latest data reveals that Traws Pharma reported Income towards Parent Company of -$4.1 million as of Q3 2025, which was up 5249.53% from -$1.2 million recorded in Q2 2025.
  • In the past 5 years, Traws Pharma's Income towards Parent Company ranged from a high of -$1.2 million in Q2 2025 and a low of -$123.3 million during Q2 2024
  • Moreover, its 5-year median value for Income towards Parent Company was -$4.6 million (2021), whereas its average is -$11.0 million.
  • Its Income towards Parent Company has fluctuated over the past 5 years, first plummeted by 257566.16% in 2024, then skyrocketed by 9898.74% in 2025.
  • Traws Pharma's Income towards Parent Company (Quarter) stood at -$3.8 million in 2021, then tumbled by 52.38% to -$5.7 million in 2022, then increased by 22.18% to -$4.5 million in 2023, then dropped by 18.29% to -$5.3 million in 2024, then grew by 23.17% to -$4.1 million in 2025.
  • Its Income towards Parent Company stands at -$4.1 million for Q3 2025, versus -$1.2 million for Q2 2025 and -$5.2 million for Q1 2025.